表紙
市場調查報告書
商品編碼
1065622

帶狀皰疹治療市場-按治療類型、管理途徑、分銷渠道:全球機會分析和行業預測(2021-2030 年)

Herpes Zoster Treatment Market by Treatment Type Route Administration and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2030

出版日期: | 出版商: Allied Market Research | 英文 205 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

2020年全球帶狀皰疹治療市場達到2.1709億美元。

預計 2021 年至 2030 年間,該市場將以 3.4% 的複合年增長率增長,到 2030 年達到 3.0342 億美元。

帶狀皰疹是由水痘-帶狀皰疹病毒在老年人體內重新激活引起的,老年人帶狀皰疹的發病率高於成人和兒童。因此,老年人口的增加和帶狀皰疹的增加也在促進市場的增長。然而,熟練專業人員的短缺預計將阻礙市場增長。相反,增加藥物開發預計將提供市場友好的增長機會。

本報告調查了全球帶狀皰疹治療市場,並提供了市場概況,以及按治療類型、給藥途徑、分銷渠道、地區和進入市場的公司概況劃分的趨勢。..

目錄

第一章介紹

第2章執行摘要

第三章市場情況

  • 市場定義和範圍
  • 主要調查結果
  • 波特五力分析
  • 定位為主要進入者,2020 年
  • 市場動態
    • 促進因素
      • 帶狀皰疹發病率和老年人口增加
    • 抑制器
      • 缺乏熟練的專業人員
    • 市場機會
      • 研發投入:某醫藥公司
    • 影響分析
  • 分析 COVID-19 對帶狀皰疹治療市場的影響

第 4 章帶狀皰疹治療市場:按治療類型

  • 概覽
    • 市場規模和預測
  • 抗病毒藥
  • 消炎藥
  • 其他

第 5 章帶狀皰疹治療市場:按管理途徑

  • 概覽
    • 市場規模和預測:按地區
  • 口語
  • 本地

第 6 章帶狀皰疹治療市場:按分銷渠道

  • 概覽
    • 市場規模和預測
  • 院內藥房
  • 藥店和零售藥店
  • 在線提供商

第 7 章帶狀皰疹治療市場:按地區

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要市場趨勢、增長動力和機遇
    • 北美市場規模和預測:按管理途徑
    • 北美市場規模和預測:按分銷渠道
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要市場趨勢、增長動力和機遇
    • 歐洲市場規模和預測:按治療類型
    • 歐洲市場規模和預測:按管理途徑
    • 歐洲市場規模和預測:按分銷渠道
    • 市場規模和預測:按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他
  • 亞太地區
    • 主要市場趨勢、增長動力和機遇
    • 亞太市場規模和預測:按治療類型
    • 亞太地區市場規模和預測:按管理途徑
    • 亞太市場規模和預測:按分銷渠道
    • 市場規模和預測:按國家/地區分類
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 韓國
      • 其他
  • 拉丁美洲、中東、非洲
    • 主要市場趨勢、增長動力和機遇
    • 拉丁美洲、中東、非洲市場規模和預測:按治療類型
    • 拉丁美洲、中東、非洲市場規模和預測:按管理途徑
    • 拉丁美洲、中東、非洲市場規模和預測:按分銷渠道
    • 市場規模和預測:按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • 其他

第 8 章公司簡介

  • ABBOTT LABORATORIES.
  • BAUSCH HEALTH COMPANIES INC.
  • CAMBER PHARMACEUTICALS
  • CIPLA INC.
  • ELI LILLY AND COMPANY
  • GLAXOSMITHKLINE PLC(GSK)
  • MERCK & COMPANY INC.
  • NOVARTIS INTERNATIONAL AG(SANDOZ)
  • PFIZER INC.
  • TEVA PHARMACEUTICALS
目錄
Product Code: LI_2113718 / A13349

The global herpes zoster treatment market was valued at $217.09 million in 2020, and is projected to reach $303.42 million by 2030, registering a CAGR of 3.4% from 2021 to 2030.

Herpes zoster (shingles) is a viral infection, caused due to the varicella-zoster virus. It is usually a painful rash on the skin that causes flickering, torment, and itchy blisters on the back, chest, and face and spreads to The rest of the body. Symptoms typically start with pain along the affected dermatome, which is followed by an enlarged vesicular eruption in 2-3 days. Symptoms include lymph nodes, fever, chills, and headache, itching, raised dots on skin and redness in that area, stabbing or shooting pain, tingling, or burning feeling in or under the skin, and upset stomach. Anyone who gets herpes zoster has a history of chickenpox, often decades earlier. These two conditions come from the same virus, called varicella zoster. In addition, individuals with herpes zoster can infect another person who never had chicken pox, yet the individual will foster chicken pox and not herpes zoster. Herpes zoster is pervasive in older adults as they have weak immune system. Individuals going through radiation treatment or chemotherapy have weakened immune system and are more inclined to get herpes zoster sickness.

In addition, PCR can be used to detect VZV DNA rapidly and sensitively, and is now widely available. After the analysis of herpes zoster, drug is given for treatment, which incorporates oral medications and antibodies. Antihistamines, desensitizing creams, gels, or fixes are given to lessen the agony. Vaccines are given to more established individuals who have a higher risk of acquiring herpes zoster.

Herpes zoster occurs due to reactivation of varicella zoster virus in older age and the incidences of herpes zoster is higher in geriatric population compared to adults and children. For instance, in 2021, the U.S. reported that the risk of herpes zoster increases with age. It has been expected that the incidence of herpes zoster in the U.S. will increase with increasing older age population.

Moreover, increase in geriatric population, coupled with rising incidences of herpes zoster also contribute toward growth of the market. However, dearth of skilled professionals is expected to hinder growth of the market. Conversely, increase in drug development provides lucrative growth opportunities to the market.

The global herpes zoster treatment market is segmented into treatment type, route of administration, distribution channel, and region. By treatment type, the market is categorized into antiviral medications, anti-inflammatory medications, and others. On the basis of route of administration, it is segregated into oral and topical. Depending on distribution channel, it is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global herpes zoster treatment market to identify the prevailing opportunities.
  • This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided.
  • Region- & country-wise analysis is provided to understand the market trends and dynamics.

KEY MARKET SEGMENTS

  • #By Treatment Type
  • ## Antiviral Medications
  • ## Anti-inflammatory Medications
  • ## Others
  • #By Route of Administration
  • ## Oral
  • ## Topical
  • #By Distribution Channel
  • ## Hospital Pharmacies
  • ## Drug Stores & Retail Pharmacies
  • ## Online Providers
  • #By Region
  • ##North America
  • ###U.S.
  • ###Canada
  • ###Mexico
  • ##Europe
  • ###Germany
  • ###France
  • ###UK
  • ###Italy
  • ###Spain
  • ###Rest of Europe
  • ##Asia-Pacific
  • ###Australia
  • ###Japan
  • ###China
  • ###India
  • ###South Korea
  • ###Rest of Asia-Pacific
  • ##LAMEA
  • ###Brazil
  • ###Saudi Arabia
  • ###South Africa
  • #KEY MARKET PLAYERS
  • ##Abbott Laboratory
  • ##Bausch Health
  • ##Cipla Inc.
  • ##Camber Pharmaceuticals.
  • ##GlaxoSmithKline plc
  • ##Merck
  • ##Novartis AG,
  • ##Pfizer Inc.,
  • ##Eli Lilly and Co.
  • ##Teva Pharmaceutical Industries Ltd###Rest of LAMEA

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five force analysis
  • 3.4.Top player positioning, 2020
  • 3.5.Market dynamics
    • 3.5.1.Driver
      • 3.5.1.1.Increase in geriatric population, coupled with rise in incidences of herpes zoster
    • 3.5.2.Restraint
      • 3.5.2.1.Dearth of skilled professionals
    • 3.5.3.Opportunities
      • 3.5.3.1.R&D investments by pharmaceutical companies
    • 3.5.4.Impact analysis
  • 3.6.COVID-19 Impact Analysis on Herpes Zoster Treatment Market

CHAPTER 4:HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Antiviral medications
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Anti-inflammatory medications
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast
    • 4.3.3.Market analysis, by country
  • 4.4.Others
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast
    • 4.4.3.Market analysis, by country

CHAPTER 5:HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast, by region
  • 5.2.Oral
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Topical
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country

CHAPTER 6:HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Hospital pharmacies
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Drug stores & retail pharmacies
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country
  • 6.4.Online providers
    • 6.4.1.Market size and forecast, by region
    • 6.4.2.Market analysis, by country

CHAPTER 7:HERPES ZOSTER TREATMENT MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.3.North America market size and forecast, By Route of administration
    • 7.2.4.North America market size and forecast, by Distribution Channel
      • 7.2.5.1.U.S
      • 7.2.5.1.1.U.S. Herpes Zoster Treatment market, by Treatment Type
      • 7.2.5.1.2.U.S. Herpes Zoster Treatment market, By Route of administration
      • 7.2.5.1.3.U.S. Herpes Zoster Treatment market, by Distribution Channel
      • 7.2.5.2.Canada
      • 7.2.5.2.1.Canada Herpes Zoster Treatment market, by Treatment Type
      • 7.2.5.2.2.Canada Herpes Zoster Treatment market, By Route of administration
      • 7.2.5.2.3.Canada Herpes Zoster Treatment market, by Distribution Channel
      • 7.2.5.3.Mexico
      • 7.2.5.3.1.Mexico Herpes Zoster Treatment market, by Treatment Type
      • 7.2.5.3.2.Mexico Herpes Zoster Treatment market, By Route of administration
      • 7.2.5.3.3.Mexico Herpes Zoster Treatment market, by Distribution Channel
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Europe market size and forecast, by Treatment Type
    • 7.3.3.Europe market size and forecast, By Route of administration
    • 7.3.4.Europe market size and forecast, by Distribution Channel
    • 7.3.5.Market size and forecast, by country
      • 7.3.5.1.Germany
      • 7.3.5.1.1.Germany Herpes Zoster Treatment market, by Treatment Type
      • 7.3.5.1.2.Germany Herpes Zoster Treatment market, By Route of administration
      • 7.3.5.1.3.Germany Herpes Zoster Treatment market, by Distribution Channel
      • 7.3.5.2.France
      • 7.3.5.2.1.France Herpes Zoster Treatment market, by Treatment Type
      • 7.3.5.2.2.France Herpes Zoster Treatment market, By Route of administration
      • 7.3.5.2.3.France Herpes Zoster Treatment market, by Distribution Channel
      • 7.3.5.3.UK
      • 7.3.5.3.1.UK Herpes Zoster Treatment market, by Treatment Type
      • 7.3.5.3.2.UK Herpes Zoster Treatment market, By Route of administration
      • 7.3.5.3.3.UK Herpes Zoster Treatment market, by Distribution Channel
      • 7.3.5.4.Italy
      • 7.3.5.4.1.Italy Herpes Zoster Treatment market, by Treatment Type
      • 7.3.5.4.2.Italy Herpes Zoster Treatment market, By Route of administration
      • 7.3.5.4.3.Italy Herpes Zoster Treatment market, by Distribution Channel
      • 7.3.5.5.Spain
      • 7.3.5.5.1.Spain Herpes Zoster Treatment market, by Treatment Type
      • 7.3.5.5.2.Spain Herpes Zoster Treatment market, By Route of administration
      • 7.3.5.5.3.Spain Herpes Zoster Treatment market, by Distribution Channel
      • 7.3.5.6.Rest of Europe
      • 7.3.5.6.1.Rest of Europe Herpes Zoster Treatment market, by Treatment Type
      • 7.3.5.6.2.Rest of Europe Herpes Zoster Treatment market, By Route of administration
      • 7.3.5.6.3.Rest of Europe Herpes Zoster Treatment market, by Distribution Channel
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Asia-Pacific market size and forecast, by Treatment Type
    • 7.4.3.Asia-Pacific market size and forecast, By Route of administration
    • 7.4.4.Asia-Pacific market size and forecast, by Distribution Channel
    • 7.4.5.Market size and forecast, by country
      • 7.4.5.1.Japan
      • 7.4.5.1.1.Japan Herpes Zoster Treatment market, by Treatment Type
      • 7.4.5.1.2.Japan Herpes Zoster Treatment market, By Route of administration
      • 7.4.5.1.3.Japan Herpes Zoster Treatment market, by Distribution Channel
      • 7.4.5.2.China
      • 7.4.5.2.1.China Herpes Zoster Treatment market, by Treatment Type
      • 7.4.5.2.2.China Herpes Zoster Treatment market, By Route of administration
      • 7.4.5.2.3.China Herpes Zoster Treatment market, by Distribution Channel
      • 7.4.5.3.Australia
      • 7.4.5.3.1.Australia Herpes Zoster Treatment market, by Treatment Type
      • 7.4.5.3.2.Australia Herpes Zoster Treatment market, By Route of administration
      • 7.4.5.3.3.Australia Herpes Zoster Treatment market, by Distribution Channel
      • 7.4.5.4.India
      • 7.4.5.4.1.India Herpes Zoster Treatment market, by Treatment Type
      • 7.4.5.4.2.India Herpes Zoster Treatment market, By Route of administration
      • 7.4.5.4.3.India Herpes Zoster Treatment market, by Distribution Channel
      • 7.4.5.5.South Korea
      • 7.4.5.5.1.South Korea Herpes Zoster Treatment market, by Treatment Type
      • 7.4.5.5.2.South Korea Herpes Zoster Treatment market, By Route of administration
      • 7.4.5.5.3.South Korea Herpes Zoster Treatment market, by Distribution Channel
      • 7.4.5.6.Rest of Asia-Pacific
      • 7.4.5.6.1.Rest of Asia-Pacific Herpes Zoster Treatment market, by Treatment Type
      • 7.4.5.6.2.Rest of Asia-Pacific Herpes Zoster Treatment market, By Route of administration
      • 7.4.5.6.3.Rest of Asia-Pacific Herpes Zoster Treatment market, by Distribution Channel
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.LAMEA market size and forecast, by Treatment Type
    • 7.5.3.LAMEA market size and forecast, By Route of administration
    • 7.5.4.LAMEA market size and forecast, by Distribution Channel
    • 7.5.5.Market size and forecast, by country
      • 7.5.5.1.Brazil
      • 7.5.5.1.1.Brazil Herpes Zoster Treatment market, by Treatment Type
      • 7.5.5.1.2.Brazil Herpes Zoster Treatment market, By Route of administration
      • 7.5.5.1.3.Brazil Herpes Zoster Treatment market, by Distribution Channel
      • 7.5.5.2.Saudi Arabia
      • 7.5.5.2.1.Saudi Arabia Herpes Zoster Treatment market, by Treatment Type
      • 7.5.5.2.2.Saudi Arabia Herpes Zoster Treatment market, By Route of administration
      • 7.5.5.2.3.Saudi Arabia Herpes Zoster Treatment market, by Distribution Channel
      • 7.5.5.3.South Africa
      • 7.5.5.3.1.South Africa Herpes Zoster Treatment market, by Treatment Type
      • 7.5.5.3.2.South Africa Herpes Zoster Treatment market, By Route of administration
      • 7.5.5.3.3.South Africa Herpes Zoster Treatment market, by Distribution Channel
      • 7.5.5.4.Rest of LAMEA
      • 7.5.5.4.1.Rest of LAMEA herpes zoster treatment market, by Treatment Type
      • 7.5.5.4.2.Rest of LAMEA Herpes Zoster Treatment market, By Route of administration
      • 7.5.5.4.3.Rest of LAMEA Herpes Zoster Treatment market, by Distribution Channel

CHAPTER 8:COMPANY PROFILES

  • 8.1.ABBOTT LABORATORIES.
    • 8.1.1.Company overview
    • 8.1.2.Operating business segment
    • 8.1.3.Product portfolio
    • 8.1.4.Business performance
  • 8.2.BAUSCH HEALTH COMPANIES INC.
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Business performance
  • 8.3.CAMBER PHARMACEUTICALS
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Key strategic moves and developments
  • 8.4.CIPLA INC.
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance.
  • 8.5.ELI LILLY AND COMPANY
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
  • 8.6.GLAXOSMITHKLINE PLC (GSK)
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance.
  • 8.7.MERCK & COMPANY INC.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
  • 8.8.NOVARTIS INTERNATIONAL AG (SANDOZ)
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
  • 8.9.PFIZER INC.
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
  • 8.10.TEVA PHARMACEUTICALS
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance

LIST OF TABLES

  • TABLE 01.GLOBAL HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 02.ANTIVIRAL MEDICATION HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 03.ANTI-INFLAMMATORY MEDICATIONS HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 04.OTHERS HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 05.ROUTE OF ADMINISTRATION HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 06.ORAL HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 07.TOPICAL HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 08.GLOBAL HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 09.HOSPITAL PHARMACIES HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 10.DRUG STORES & RETAIL PHARMACIES HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.ONLINE PROVIDERS DISTRIBUTION CHANNELS HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 12.HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 14.NORTH AMERICA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 15.NORTH AMERICA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 17.U.S. HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 18.U.S. HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 19.RETAIL PHARMACIES AND HOSPITAL PHARMACIES SEGMENT COLLECTIVELY U.S. HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 20.CANADA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 21.CANADA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 22.CANADA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 23.MEXICO HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 24.MEXICO HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 25.MEXICO HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 26.EUROPE HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 27.EUROPE HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 28.EUROPE HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 29.EUROPE HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 30.GERMANY HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 31.GERMANY HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 32.GERMANY HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 33.FRANCE HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 34.FRANCE HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 35.FRANCE HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 36.UK HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 37.UK HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 38.UK HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 39.ITALY HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 40.ITALY HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 41.ITALY HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 42.SPAIN HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 43.SPAIN HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 44.SPAIN HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 45.REST OF EUROPE HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 46.REST OF EUROPE HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 47.REST OF EUROPE HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 48.ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 49.ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 50.ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 51.ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 52.JAPAN HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 53.JAPAN HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 54.JAPAN HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 55.CHINA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 56.CHINA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 57.CHINA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 58.AUSTRALIA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 59.AUSTRALIA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 60.AUSTRALIA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 61.INDIA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 62.INDIA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 63.INDIA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 64.SOUTH KOREA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 65.SOUTH KOREA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 66.SOUTH KOREA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 67.REST OF ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 68.REST OF ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 69.REST OF ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 70.LAMEA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 71.LAMEA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 72.LAMEA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 73.LAMEA HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 74.BRAZIL HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 75.BRAZIL HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 76.BRAZIL HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 77.SAUDI ARABIA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 78.SAUDI ARABIA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 79.SAUDI ARABIA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 80.SOUTH AFRICA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 81.SOUTH AFRICA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 82.SOUTH AFRICA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 83.REST OF LAMEA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
  • TABLE 84.REST OF LAMEA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 85.REST OF LAMEA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 86.ABBOTT: COMPANY SNAPSHOT
  • TABLE 87.ABBOTT: OPERATING SEGMENT
  • TABLE 88.ABBOTT: PRODUCT PORTFOLIO
  • TABLE 89.BAUSCH: COMPANY SNAPSHOT
  • TABLE 90.BAUSCH: OPERATING SEGMENTS
  • TABLE 91.BAUSCH: PRODUCT PORTFOLIO
  • TABLE 92.CAMBER: COMPANY SNAPSHOT
  • TABLE 93.CAMBER: OPERATING SEGMENTS
  • TABLE 94.CAMBER: PRODUCT PORTFOLIO
  • TABLE 95.CAMBER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 96.CIPLA: COMPANY SNAPSHOT
  • TABLE 97.CIPLA: OPERATING SEGMENTS
  • TABLE 98.CIPLA: PRODUCT PORTFOLIO
  • TABLE 99.LILLY: COMPANY SNAPSHOT
  • TABLE 100.LILLY: OPERATING SEGMENTS
  • TABLE 101.LILLY: PRODUCT PORTFOLIO
  • TABLE 102.GSK: COMPANY SNAPSHOT
  • TABLE 103.GSK: OPERATING SEGMENTS
  • TABLE 104.GSK: PRODUCT PORTFOLIO
  • TABLE 105.MERCK: COMPANY SNAPSHOT
  • TABLE 106.MERCK: OPERATING SEGMENTS
  • TABLE 107.MERCK: PRODUCT PORTFOLIO
  • TABLE 108.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 109.NOVARTIS: OPERATING SEGMENTS
  • TABLE 110.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 111.PFIZER: COMPANY SNAPSHOT
  • TABLE 112.PFIZER: OPERATING BUSINESS SEGMENTS
  • TABLE 113.PFIZER: PRODUCT PORTFOLIO
  • TABLE 114.TEVA: COMPANY SNAPSHOT
  • TABLE 115.TEVA: OPERATING SEGMENTS
  • TABLE 116.TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.GLOBAL HERPES ZOSTER TREATMENT MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 04.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 05.HIGH THREAT OF SUBSTITUTES
  • FIGURE 06.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07.HIGH INTENSITY OF RIVALRY
  • FIGURE 08.TOP PLAYER POSITIONING, 2020
  • FIGURE 09.IMPACT ANALYSIS
  • FIGURE 10.COMPARATIVE ANALYSIS OF ANTIVIRAL MEDICATION HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 11.COMPARATIVE ANALYSIS OF ANTI-INFLAMMATORY MEDICATIONS HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 12.COMPARATIVE ANALYSIS OF OTHERS HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 13.COMPARATIVE ANALYSIS OF ORAL HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 14.COMPARATIVE ANALYSIS OF TOPICAL HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 15.COMPARATIVE ANALYSIS OF HOSPITAL PHARMACIES HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 16.COMPARATIVE ANALYSIS OF DRUG STORES & RETAIL PHARMACIES HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 17.COMPARATIVE ANALYSIS OF ONLINE PROVIDERS DISTRIBUTION CHANNELS HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • FIGURE 18.ABBOTT: NET SALES, 2020 ($MILLION)
  • FIGURE 19.ABBOTT: REVENUE SHARE PER SEGMENT 2020(%)
  • FIGURE 20.ABBOTT: REVENUE SHARE, BY REGION 2020(%)
  • FIGURE 21.BAUSCH: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 22.BAUSCH: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 23.BAUSCH: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 24.CIPLA: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 25.CIPLA: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 26.LILLY: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 27.LILLY: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 28.LILLY: REVENUE SHARE, BY REGION, 2020(%)
  • FIGURE 29.GSK: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 30.GSK: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 31.GSK: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 32.MERCK: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 33.MERCK: REVENUE SHARE, BY PRODUCT, 2020 (%)
  • FIGURE 34.MERCK: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 35.NOVARTIS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 36.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 37.NOVARTIS: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 38.PFIZER: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 39.PFIZER: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 40.TEVA.: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 41.TEVA: REVENUE SHARE, BY REGION, 2020 (%)